[1]李刚刚,刘清民,马慧群.西罗莫司在皮肤科中的应用进展[J].中国皮肤性病学杂志,2019,(05):590-594.[doi:10.13735/j.cjdv.1001-7089.201811088]
 LI Ganggang,LIU Qingmin,MA Huiqun.The Application of Sirolimus in Skin Diseases[J].The Chinese Journal of Dermatovenereology,2019,(05):590-594.[doi:10.13735/j.cjdv.1001-7089.201811088]
点击复制

西罗莫司在皮肤科中的应用进展
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2019年05期
页码:
590-594
栏目:
基层园地
出版日期:
2019-04-01

文章信息/Info

Title:
The Application of Sirolimus in Skin Diseases
文章编号:
1001-7089(2019)05-0590-05
作者:
李刚刚刘清民马慧群
西安交通大学第二附属医院,陕西 西安 710004
Author(s):
LI GanggangLIU Qingmin MA Huiqun
(Department of Dermatology, the Second Affiliated Hospital of Xi′an Jiaotong University, Xi′an 710004, China)
关键词:
西罗莫司皮肤疾病应用
Keywords:
SirolimusSkin diseasesApplication
分类号:
R 986
DOI:
10.13735/j.cjdv.1001-7089.201811088
文献标志码:
A
摘要:
西罗莫司(亦称雷帕霉素),于1971年由加拿大Wyeth-Ayerst研究所分离得到的一种31元大环内酯类抗生素,最初用作抗菌药物,但随后的研究显示其具有显著的抗肿瘤、抗增殖和免疫抑制作用,并于1999年9月由美国FDA批准作为新型免疫抑制剂上市,其独特的作用机制和显著效力,使该药物的临床应用越来越受到人们的关注,在临床上的使用领域不断扩大,在皮肤科中有较好的应用前景。本文对西罗莫司在皮肤科的研究、可能的作用机制、疗效、不良反应、展望等方面进行阐述,旨在对皮肤科疾病的治疗提供更多思路和更多选择。
Abstract:
Sirolimus(Rapamycin), a 31-membered macrolide antibiotic, was first isolated from soil sample by the Canada Wyeth-Ayerst institution in 1975.Sirolimus was originally used as an antifungal agent.However, subsequent studies showed that it had significant anti-tumor, anti-proliferation and immunosuppression effects.US FDA approved it as an immunosuppressant in September 1999.Due to its unique mechanism and remarkable effects, its clinical application has attracted more attention, making it exhibit broad application prospects in dermatology.This paper summarizes the clinical studies of sirolimus in the treatment of skin diseases, the possible mechanism of its action, the efficacy, adverse effects and its application prospects in order to provide more options for the treatment of skin diseases.

参考文献/References:


[1]Banaszynski LA,Liu CW,Wandless TJ.Characterization of the FKBP rapamycin FRB ternary complex[J].J Am Chem Soc,2005,127 (13): 4715-4721.
[2] Arriola Apelo SI, Lamming DW.Rapamycin: An inhibiTOR of aging emerges from the soil of easter Island[J].J Gerontol A Biol Sci Med Sci, 2016,71(7):841-849.
[3] Sehgal SN.Sirolimus: its discovery, biological properties, and mechanism of action [J].Transplant Proc,2003,35 (3 Suppl): 7S-14S.
[4] 王晓情.西罗莫司的研究进展[J].医学综述,2006,12(21):1338-1340.
[5] 张斌,马琳.西罗莫司在脉管性疾病中的应用[J].皮肤科学通报,2018,35(5):452-456.
[6] Adams DM, Trenor CC,Hammill AM,et al.Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies[J].Pediatrics,2016,137(2):e20153257.
[7] Marignol L, Coffey M, Lawler M, et al.Hypoxia in prostate cancer: a powerful shield against tumour destruction? [J] Cancer Treat Rev,2008,34(4):313-327.
[8] Guba M, Yezhelyev M,Eichhorn ME,et al.Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF[J].Blood,2005,105(11):4463-4469.
[9] Oza VS,Mamlouk MD,Hess CP.et al.Role of sirolimus in advanced kaposiform hemangioendothelioma[J].Pediatr Dermatol,2016,33(2):e88-92.
[10] Salloum R, Fox CE, Alvarez-Allende CR, et al, Response ofblue rubber bleb nevus syndrome to sirolimus treatment[J].Pediatr Blood Cancer, 2016,63(11):1911-1914.
[11] Madankumar R,Teperman LW,Stein JA.Use of etanercept for psoriasis in a liver transplant recipient[J].JAAD Case Rep,2015,1(6):S36-S37.
[12] Bieber,Thomas.Atopic dermatitis[J].Annal Dermatol,2010, 22(2): 125-137.
[13] Svensson A,Chambers C, G nemo A,et al.A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis[J].Curr Med Res Opin, 2011 ,27(7):1395-1406.
[14] Yang F,Tanaka M,Wataya-Kaneda M,et al.Topical application of rapamycin ointment ameliorates Dermatophagoides farina body extract-induced atopic dermatitis in NC/Nga mice[J].Exp Dermatol,2014,23(8):568-572.
[15] Mahévas T, Bertinchamp R, Battistella M, et al.Efficacy of oral sirolimus as salvage therapy in refractory lichen planus associated with immune deficiency[J].Br J Dermatol,2018,179(3):771-773.
[16] Abraham RT,Gibbons JJ.The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy[J].Clin Cancer Res,2007,13(11):3109-3114.
[17] Lockshin, Richard A, Zakeri, et al.Caspase-independent cell deaths[J].Curr Opin Cell Biol, 2002,14(6):727-733.
[18] Jin SV,White E.Tumor suppression by autophagy through the management of metabolic stress[J].Autophagy,2008,4(5):563-566.
[19] Winslow,Ashley R,Rubinsztein,et al.Autophagy in neurodegeneration and development[J].Biochimica Biophy Acta, 2008, 1782(12): 723-9.
[20] Sehgal SN.Sirolimus:its discovery,biological properties,and mechanism of action[J].Transplant Proc,2003,35(3 Suppl):7S-14S.
[21] Triana P,Dore M,Cerezo VN,et al.Sirolimus in the treatment of vascular anomalies[J].Eur J Pediatr Surg,2017,27(1):86-90.
[22] Oza VS,Mamlouk MD,Hess CP,et al.Role of Sirolimus in advanced kaposiform hemangioendothelioma[J].Pediatr Dermatol,2016,33(2):e88-92.
[23] Salloum R,Fox CE,Alvarez-Allende CR,et al.Response of blue rubber bleb nevus syndrome to sirolimus treatment[J].Pediatr Blood Cancer,2016,63(11):1911-1914.
[24] Zhuo KY,Russell S,Wargon O,et al.Localised intravascular coagulation complicating venous malformations in children:Associations and therapeutic options[J].J Paediatr Child Health,2017,53(8):737-741.
[25] García-Montero P,Del Boz J,Sanchez-Martínez M,et al.Microcystic lymphatic malformation successfully treated with topical rapamycin[J].Pediatrics,2017,139(5): e2016-2105.
[26] Bürger C,Shirsath N,Lang V,et al.Blocking mTOR signalling with rapamycin ameliorates imiquimod-induced psoriasis in mice[J].Acta Derm Venereol,2017,97(9):1087-1094.
[27] Zhou L,Du GS,Pan LC,et al.Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation:A single center experience[J].Oncol Lett,2017,14(6):7817-7824.
[28] Bieber,Thomas.Atopic Dermatitis[J].Annal Dermatol,2010, 22(2): 125-137.
[29] Svensson A,Chambers C,G nemo A,et al.A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis[J].Curr Med Res Opin, 2011,27(7):1395-1406.
[30] Trautmann A,Akdis M, Schmid-Grendelmeier P,et al.Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis[J].J Allergy Clin Immunol.2001 .108(5):839-846.
[31] 金文玉,方宇辉,朱莲花,等.西罗莫司软膏对小鼠特应性皮炎的治疗作用及其机制[J].山东医药,2018,58(28):11-15.
[32] Tsukahara K,Nakagawa H,Moriwaki S,et al.Inhibition of ultraviolet-B-induced wrinkle formation by an elastase-inhibiting herbal extract: implication for the mechanism underlying elastase-associated wrinkles[J].Int J Dermatol,2006,45(4):460-468.
[33] Trakatelli M,Ulrich C,del Marmol V,et al.Epidemiology of nonmelanoma skin cancer (NMSC)in Europe:accurate and comparable data are needed for effective public health monitoring and interventions[J].Br J Dermatol,2007,156 (Suppl 3):1-7.
[34] 张青松,鞠梅,陈崑,等.培养的人皮肤成纤维细胞光老化模型中自噬水平的研究[J].中华皮肤科杂志,2010,43(8):572-574.
[35] Fingar DC,Blenis J.Target of rapamycin (TOR):an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression [J].Oncogene,2004,23(18):3151-3171.
[36] 方晓波,周炳荣,骆丹,等.自噬促进剂西罗莫司对中波紫外线诱导成纤维细胞提早衰老的影响[J].中华皮肤科杂志,2013,46(8):579-582.
[37] Kellenberger AJ,Tauchi M.Mammalian target of rapamycin complex 1 (mTORC1) may modulate the timing of anagen entry in mouse hair follicles[J].Exp Dermatol,2013,22(1):77-80.
[38] 吴绍熙,郭宁如.大环内酯类免疫抑制剂在皮肤科的研究与应用[J].临床皮肤科杂志,2003,32(10) :620-622.
[39] Mahévas T,Bertinchamp R,Battistella M,et al.Efficacy of oral sirolimus as salvage therapy in refractory lichen planus associated with immune deficiency[J].Br J Dermatol,2018,179(3):771-773.
[40] Soria A,Agbo-Godeau S,Ta eb A,et al.Treatment of refractory oral erosive lichen planus with topical rapamycin: 7 cases[J].Dermatol,2009,218(1),22-25.
[41] Liu F,Zhang H,Zhang K,et al.Rapamycin promotes Schwann cell migration and nerve growth factor secretion[J].Neural Regen Res,2014,9(6):602-609.

相似文献/References:

[1]闫慧敏,姜薇.人类皮肤微生物群和皮肤疾病[J].中国皮肤性病学杂志,2015,(12):1292.[doi:10.13735/j.cjdv.1001-7089.201412052]
 YAN Hui min,JIANG Wei.The Human Skin Microbiome and Skin Diseases[J].The Chinese Journal of Dermatovenereology,2015,(05):1292.[doi:10.13735/j.cjdv.1001-7089.201412052]

备注/Memo

备注/Memo:

[作者单位]西安交通大学第二附属医院,陕西 西安 710004
[通讯作者]马慧群,E-mall:mahuiqun2003@163.com
更新日期/Last Update: 2019-04-15